ClariVest Asset Management LLC Sells 2,700 Shares of Repligen Co. (NASDAQ:RGEN)

ClariVest Asset Management LLC lessened its position in shares of Repligen Co. (NASDAQ:RGENGet Rating) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,170 shares of the biotechnology company’s stock after selling 2,700 shares during the period. ClariVest Asset Management LLC’s holdings in Repligen were worth $7,196,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of RGEN. Confluence Wealth Services Inc. bought a new stake in Repligen during the fourth quarter worth $27,000. Sageworth Trust Co of South Dakota acquired a new position in shares of Repligen during the fourth quarter worth $46,000. Assetmark Inc. acquired a new position in shares of Repligen during the third quarter worth $49,000. UMB Bank N A MO acquired a new position in shares of Repligen during the fourth quarter worth $59,000. Finally, Fieldpoint Private Securities LLC increased its holdings in shares of Repligen by 36.8% during the third quarter. Fieldpoint Private Securities LLC now owns 260 shares of the biotechnology company’s stock worth $75,000 after buying an additional 70 shares in the last quarter. Institutional investors own 86.82% of the company’s stock.

In other news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total transaction of $396,060.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.10% of the company’s stock.

A number of analysts recently weighed in on the company. SVB Leerink decreased their price objective on Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, February 18th. initiated coverage on Repligen in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price target on the stock. in a research report on Monday, February 21st. Finally, Craig Hallum cut their price target on shares of Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $285.57.

Shares of RGEN stock traded down $0.29 on Wednesday, reaching $151.14. 6,450 shares of the company were exchanged, compared to its average volume of 503,429. The company has a market cap of $8.23 billion, a price-to-earnings ratio of 60.15 and a beta of 0.98. The company has a 50-day moving average of $164.36 and a 200-day moving average of $202.98. Repligen Co. has a one year low of $137.21 and a one year high of $327.32.

Repligen (NASDAQ:RGENGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.72 by $0.20. The firm had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The company’s revenue for the quarter was up 44.5% on a year-over-year basis. During the same quarter last year, the business posted $0.68 EPS. Equities research analysts predict that Repligen Co. will post 3.1 EPS for the current fiscal year.

About Repligen (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.